GILD

#79
Gilead Sciences Inc
140.45 USD
+1.02%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
140.45
140.45
Intervallo Annuale
95.29
157.27
Variazione giornaliera
+1.02%
Variazione Mensile
-2.62%
Variazione di 6 mesi
+18.94%
Variazione Annuale
+32.00%
Chiusura Precedente
139.03
Apertura
140.45
Bid
Ask
Minimo
140.45
High
140.45
Volume
325
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
  • Market Capitalization 174.36 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
18.1
Rapporto prezzo/fatturato
5.23
Dividendi per azione
3.16
Rendimento da dividendi %
2.57

Gilead Sciences Inc

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.

Notizie